JW Therapeutics Advances Cancer Treatment with NMPA Acceptance

JW (Cayman) Therapeutics Co. Ltd. ( (HK:2126) ) has provided an announcement.

JW Therapeutics announced that the National Medical Products Administration of China has accepted the supplemental Biological License Application for Carteyva® as a second-line treatment for relapsed or refractory large B-cell lymphoma in patients ineligible for autologous stem cell transplantation. This development is supported by positive clinical results showing significant response rates and safety, addressing the urgent need for effective treatments for patients who cannot undergo standard therapies. The acceptance of this application could enhance JW Therapeutics’ position in the biotechnology industry and provide new hope for patients with limited treatment options.

More about JW (Cayman) Therapeutics Co. Ltd.

JW Therapeutics is an independent biotechnology company focused on developing, manufacturing, and commercializing cell immunotherapy products. Founded in 2016, the company has built an integrated platform for product development in cell immunotherapy, targeting hematologic malignancies, solid tumors, and autoimmune diseases. JW Therapeutics aims to bring breakthrough cell immunotherapy products to patients in China and beyond, contributing to the development of China’s cell immunotherapy industry.

Average Trading Volume: 1,425,487

Technical Sentiment Signal: Sell

Current Market Cap: HK$724.2M

For detailed information about 2126 stock, go to TipRanks’ Stock Analysis page.